Efficacy and Safety of Low-Dose Brexpiprazole for Acute Schizophrenia: Meta-Analysis of Randomized Placebo-Controlled Trials

Overview of attention for article published in Neuropsychiatric Disease and Treatment, August 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Good Attention Score compared to outputs of the same age and source (66th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 4,966 followers.

RT @chrisaikenmd: New analysis warns against low dose brexpiprazole (Rexulti) in #Schizophrenia. Below 2 mg/day it mostly added side effect…

RT @chrisaikenmd: New analysis warns against low dose brexpiprazole (Rexulti) in #Schizophrenia. Below 2 mg/day it mostly added side effect…

New analysis warns against low dose brexpiprazole (Rexulti) in #Schizophrenia. Below 2 mg/day it mostly added side effects without any benefits. https://t.co/ehcRAELW1M https://t.co/DIPeiiqfHD

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.